Senesco Technologies, Inc. (AMEX:SNT)
About Senesco Technologies, Inc. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.
Statistics Symbol
SNT
Beta:
1.25
Current Price
$0.30
Market Capitalization:
20.36M
52 week range
$0.22 - $0.75
Shares Outstanding
67.71B
Avg Volume
193,634.00
Float:
54.66M
Financials As the company is in its development stage it has not generated any revenue yet. Senesco Technologies, Inc. (AMEX:SNT) reported the net loss of $3.02 million for the quarter ended September 30 th, 2010 resulting in loss of $0.05 per share for the respective quarter. The company’s total assets accumulate up to $11.96 million with highest proportion of current assets standing at $7.28 million as on September 30 th, 2010. The company maintains the current ratio of 2.11 times which depicts that current assets are enough to cover the current liabilities by 2.11 times. The company’s high short term liquidity position is also evident from the fact that its cash and cash equivalents of $6.29 million covers the current liabilities by 1.82 times. The company’s total liabilities stand at $4.75 million as compared to its total equity of $7.21 million.
Palatin Technologies, Inc. (AMEX:PTN)
About Palatin Technologies, Inc. Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company engaged in the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems. As of June 30, 2010, the Company had three drug development programs, including Bremelanotide, Peptide melanocortin receptor agonists and PL-3994. Bremelanotide is a peptide melanocortin receptor agonist. PL-3994 is a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of acute exacerbations of asthma, heart failure and refractory or difficult-to-control hypertension.
Statistics Symbol
PTN
Beta:
1.14
Current Price
$1.09
Market Capitalization:
12.90M
52 week range
$0.84 - $3.70
Shares Outstanding
11.84M
Avg Volume
62,835.00
Float:
10.91M
Financials As per its last financials statements ending September 30 th, 2010 Palatin Technologies, Inc. (AMEX:PTN) generated the total revenue of $0.22 million for the quarter. The company resulted in the net loss of $4.60 million resulting in loss of $0.39 per share for the respective quarter. The company’s total assets accumulate up to $8.39 million with highest proportion of current assets in its composition standing at $5.56 million. The company maintains strong short term liquidity positions with current ratio of 2.44 times depicting that company’s current assets are 2.44 times more than its current liabilities. PTN total liabilities stand at $3.30 million as compared to the total equity of $8.39 million as September 30th, 2010.
Uluru Inc. (AMEX:ULU)
About Uluru Inc. ULURU Inc. (ULURU) is a diversified specialty pharmaceutical company. The Company is focused in the developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc drug delivery technologies. ULURU’s Nanoflex technology system has at its core a system of hydrogel-like nanoparticles composed of a polymer used in manufacturing contact lenses and other the United States Food and Drug Administration (FDA)-approved implants. Utilizing its Nanoflex technology, it has developed three separate development platforms from the system: Nanoflex Powder, Nanoflex Gel and Nanoflex Injectable Liquid. Its Nanoflex Powder is composed of hydrogel particle flakes that aggregate immediately and irreversibly upon contact with physiological fluid, such as wound exudate, forming a nonresorbable film. Its Nanoflex technology is composed of hydrated nanoparticles that are concentrated into a viscoelastic gel.
Statistics Symbol
ULU
Beta
1.44
Current Price
$0.11
Market Capitalization:
9.65,
52 week range
$0.08 -$ 0.30
Shares Outstanding
84.12M
Avg Volume
777,807.00
Float:
63.12M
Financials As per its last financial statements ending September 30 th, 2010 Uluru Inc. (AMEX:ULU) generated the total revenue of $0.06 for the quarter however ended in net loss of $1.21 million resulting in loss of $0.01 per share. The company’s total assets accumulate up to $10.21 million with highest proportion of fixed assets in its composition. The company maintains the current ratio of 2.52 times depicting that current assets cover the current liabilities by 2.52 times. ULU maintains a strong capital structure with total liabilities $2.61 times as compared to total equity of $7.60 million as per its latest balance sheet.
DISCLAIMER
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.
We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future
email regarding a specific company will be the result of an advertising and promotional campaign for which Seo Freisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. Seo Freisin and its affiliates currently hold no shares in the profiled company.
Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).